ImQuest receives two-year grant to develop pyrimidinedione product as anti-HIV topical microbicide
Published: 2008-08-14 06:55:00
Updated: 2008-08-14 06:55:00
Samjin Pharm says that its AIDS treatment co-developer successfully acquired funding from the National Institute of Allergy and Infectious Disease (NIAID/NIH) to support the development of pyrimidinedione inhibitors as topical microbicides to prevent the sexual transmission of HIV.
The two-yea...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
